Consistent with this, the overexpression of SETD8 has been reported in many different solid tumors [14–17] and pharmacological inhibition of SETD8 is sufficient to activate the p53 pro-apoptotic program in neuroblastoma cell lines [18]. This evidence concerns the gene KMT5A and neuroblastoma.